

Targeting acetylcholinesterase with halogenated ligands: finding halogen bonding hotspots


Bernardo Henriques, Paulo J. Costa

Centro de Química e Bioquímica, Faculdade de Ciências da Universidade de Lisboa, 1749-016 Lisboa, Portugal AND BioISI - Biosystems & Integrative Sciences Institute, Faculdade de Ciências da Universidade de Lisboa, Portugal. Email: bernardohenriques97@gmail.com


Introduction

Halogen Bonds (HaBs)

Halogen bonds ($R-X\cdots B$) are noncovalent interactions between a positive region on the electrostatic potential of halogen ($X = \text{Cl}, \text{Br}, \text{I}$), called σ -hole, and a nucleophile, such as a lone pair of a Lewis base (B).




HaBs are linear interactions, orthogonal to interactions of the type $R-X\cdots E$ ($E = \text{electrophile}$). [1]



Halogen Bonding in biomolecular systems


Halogen atoms have an important role in drug design. Given their ability to form HaBs, they are also becoming a tool in protein-ligand recognition.



A good example of this phenomena is the X-ray crystal structure of cobimetinib in complex with MEK1 kinase (PDB ID: 4LMN). Cobimetinib is a kinase inhibitor approved for the treatment of BRAF-mutant melanoma. [2]

Objective


There are virtually no reports on the use of HaBs to target acetylcholinesterase (AChE).



Can we find HaBs hotspots in AChE?

Methods



New method to find AChE HaBs hotspots




Results

HaBs frequency

Each acceptor type shows distinct propensity for halogen bonding. With backbone C=O and sidechain COO^- being the most favored acceptor types, followed by sidechain OH.



HaBs hotspots



References

[1] P. J. Costa, *Phys. Sci. Rev.* **2017**, 2, 20170136. [2] P. J. Costa, R. Nunes, D. Vila-Viçosa, *Expert Opin. Drug Discov.* **2019**, 14, 805–820. [3] M. R. Koebel, G. Schmadeke, R. G. Posner, S. Sirimulla, *J. Cheminformatics.* **2016**, 8, 1–8. [4] J. Cheung, J. J. Height, *et al.*, *J. Med. Chem.* **2012**, 55, 10282–10286. [5] Z. Xu, W. Zhu, *et al.*, *J. Chem. Inf. Model.* **2014**, 54, 69–78

Funding

FCT/MCTES (IF/00069/2014, IF/00069/2014/CP1216/CT0006, SFRH/BD/116614/2016, UID/MULTI/00612/2019 and UID/MULTI/04046/2019). FCT/MCTES, Lisboa 2020, Portugal 2020, FEDER/FN, and European Union (LISBOA-01-0145-FEDER-028455, PTDC/QUI-QFI/28455/2017)